Cipla expects its North American business to remain supported by its upcoming product pipeline, the drugmaker said on Tuesday, even as intensifying competition and tapering sales of generic Revlimid weighed on its US performance in the September quarter.
India’s third-largest drugmaker by revenue reported a 35% year-on-year decline in consolidated net profit to Rs 878 crore for the second quarter of FY27, missing analysts’ estimates of Rs 942 crore, according to data compiled by LSEG. Net profit stood at Rs 1,351 crore in the year-ago quarter.
